Qilu Pharmaceuticals" Celexib Capsules was approved for sale.

On September 16th, the official website of the State Drug Administration showed that Qilu Class 4 generic drug "Selesib Capsules" had been approved for market as a consistent evaluation.
as a new generation of nonsteroidal anti-inflammatory analgesics, celexib inhibits prostatin production by selectively inhibiting cyclooxidase-2 (COX-2) to achieve anti-inflammatory and analgesic effects.
, originally owned by Pfizer, was listed in the United States in 2002 and is owned by GD SEARLE LLC.
was approved for listing by NMPA in 2012 and is currently approved for osteoarthritis (OA), rheumatoid arthritis (RA), early childhood rheumatoid arthritis (JRA), mandatory spinal inflammation (AS) in patients aged two and over.
's global sales peaked at $3 billion, and the approval of generic drugs after the patent expired in 2014 has had a significant impact on Celeste's sales, which have declined significantly.
2019, Celesl's global sales will be only $700 million.
Insight database shows that in addition to Pfizer's Sereb capsules (commodity name: Xilexi) approved for import, there are six other enterprises including Hengrui, Shi medicine has been approved.
, nine companies are in the listing application and eight have conducted BE trials.
statistics for the standards and enterprises in the chart.
from: Insight database () Celexibu oral regular release preparation (200mg specification) for the third batch of national collection varieties, a total of six enterprises to compete, the winning enterprises including Stone Pharmaceuticals Europe, Qingdao Baiyang, Sichuan Guowei, Zheng Daqingjiang four, the decline of 93.7%, 92.2%, 88.7%, 86.4%, single-piece quotation in 0.313 yuan to 0.683 yuan.
: The above reduction is calculated in terms of (quote-limit price)/limit price, and is calculated by the non-difference ratio rule.